Earlier studies have shown that modification of the octapeptide octreotide in positions 3 and 8 may result in compounds with increased somatostatin receptor affinity that, if radiolabelled, display improved uptake in somatostatin receptor-positive tumours. The aim of a recent research study in our laboratory was to employ the parallel peptide synthesis approach by further exchanging the amino acid in position 3 of octreotide and coupling the macrocyclic chelator DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to these peptides for labelling with radiometals like gallium-67 or -68, indium-111, yttrium-90 and lutetium-177. The purpose was to find radiopeptides with an improved somatostatin receptor binding profile in order to extend the spectrum of targeted tumours. In]DOTA-OC). The internalized radiopeptides were externalized intact upon 2 h of internalization followed by an acid wash. After 2-3 h of externalization a plateau is reached, indicating a steadystate situation explained by reactivation of the receptors followed by re-endocytosis. Biodistribution studies in CA 20948 tumour-bearing rats showed rapid clearance from all sstr-negative tissues except the kidneys. At 4 h the uptake of [ 111 In]DOTA-NOC in the tumour and sstr-positive tissues, such as adrenals, stomach and pancreas, was three to four times higher than that of [ 111 In]DOTA-TOC. Differential blocking studies indicate that this is at least partially due to the uptake mediated by sstr3 and sstr5. These very promising preclinical data justify the use of this new radiopeptide for imaging and potentially internal radiotherapy studies in patients.
Introduction
Radiopeptides are becoming of increasing interest in tumour targeting for either the localization or the internal radiotherapy of neoplasms [1, 2, 3, 4, 5, 6, 7, 8, 9] . Analogues of the somatotropin release inhibiting factor (SRIF), somatostatin, radiolabelled with a variety of gamma-, positron-and beta-emitters, are the prototypes of such peptides. Somatostatin is a cyclic peptide hormone that occurs naturally in two bioactive molecular forms: somatostatin-14 and its N-terminally extended form, somatostatin-28. It exerts different biological effects in different parts of the body such as the brain, the pituitary, the pancreas, the gut and some components of the immune system. The effects include inhibition of hormone secretion and modulation of neurotransmission and cell proliferation. These actions are mediated by specific, Gprotein-coupled receptors. Today five different somatostatin receptor subtypes have been characterized and cloned (sstr1-5). They are responsible for different biological responses. As some of these receptors are overexpressed in several human tumours, especially neuroendocrine tumours and their metastases, these tumours can be visualized in vivo by radiometal chelator conjugated somatostatin analogues like [ 111 In-DTPA-D-Phe 1 ]-octreotide (OctreoScan) [10] . It has also been shown that somatostatin receptor scintigraphy using this agent is the most sensitive method for localization of primary and metastatic disease in endocrine pancreatic tumours and carcinoids except insulinomas [11] . New conjugates may show higher sensitivity with regard to the localization of tumours and metastases, e.g. 99m Tc-depreotide is registered in many countries and appears to show good performance in the evaluation of solitary pulmonary nodules [12] , in breast tumours and even in melanoma [13] . On the other hand, a recent study comparing OctreoScan with 99m Tc-depreotide in 44 patients with neuroendocrine tumours showed that the 111 In-labelled peptide yielded a far higher detection rate for neuroendocrine tumours, especially for liver metastases [14] . 111 In]DOTA-TOC and [ 90 Y]DOTA-TOC (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) have been shown to be effective targeting and therapeutic agents in animal models and patients [15, 16, 17, 18, 19, 20, 21, 22, 23] . In addition, replacement of the alcohol group at the C-terminus of the octapeptide by a carboxylic acid group led to increased sstr2 affinity [24] , and [ 177 Lu-DOTA]-D-Phe 1 -Tyr 3 -Thr 8 -octreotide ([ 177 Lu]DOTA-TATE) showed higher tumour uptake than [ 111 In-DTPA]-octreotide in six patients with somatostatin receptor-positive tumours [25] . These new radiopeptides show distinctly higher sstr2 affinity compared with OctreoScan. Nevertheless, they bind with high affinity only to sstr2: their affinity to sstr5 is low, and that to sstr3 almost negligible; no affinity of these new compounds was found to sstr1 and sstr4. Although the majority of tumours studied with radiolabelled somatostatin analogues express mainly sstr2 [26] , recent literature data indicate that also sstr1 and sstr3-5 may be present in some human tumours. For example, in binding studies using [ 125 I]-RC-160 (D-Phe-Cys-Tyr-D-Trp-LysVal-Cys-Trp-NH 2 ; K D =6.55 nM) as the radioligand, Halmos et al. [27] found somatostatin receptors to be present on 76% of human epithelial ovarian cancers. By use of in situ hybridization, Reubi et al. found m-RNAs of sstr1, 2 and 3 in a variety of human tumours, including GH-adenoma [28] . Forssell-Aronsson et al. reported the lack of sstr2 (except for medullary thyroid carcinoma) with Northern blot in most of the thyroid tumours studied in 68 patients. Nevertheless, all tumour types regularly expressed sstr1, sstr3, sstr4 and sstr5 [29] . Raderer [31] . However, their claim that this peptide targets sstr2-5 with high affinity and sstr1 with lower affinity could not be confirmed by Reubi et al. [24] . To extend the biological activity profile of radiolabelled somatostatin analogues, we started a programme to synthesize radiopeptides with affinity to all somatostatin receptor subtypes in order to potentially extend the spectrum of accessible tumours in diagnosis and internal radiotherapy. A first compound resulted from a parallel synthesis approach exchanging the amino acid in position 3 of octreotide; this led to a radiopeptide, 
Materials and methods
All chemicals were obtained from commercial sources and used without further purification. H-Thr(tBu)-ol-(2-chloro-trityl)-resin was obtained from Advanced ChemTech (Giessen, Germany) and Fmoc (9-fluorenylmethoxycarbonyl) amino acids were purchased from NovaBiochem AG (Läufelfingen, Switzerland), Bachem (Bubendorf, Switzerland) and Neosystems (France). 111 InCl 3 was obtained from Mallinckrodt Medical (Petten, The Netherlands). The prochelator DOTA(tBu) 3 (4,7,10-tricarboxymethyl-tert-butyl ester 1,4,7,10-tetraazacyclododecane-1-acetate) was synthesized according to Heppeler et al. [32] or purchased from Macrocyclics (Richardson, Tex., USA). The reactive side chains of the amino acids were masked with one of the following groups: Cys, acetamidomethyl; Lys, t-butoxycarbonyl; Thr, t-butyl; Trp, t-butoxycarbonyl. Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was carried out on a Hewlett Packard 1050 HPLC system (Waldbronn, Germany) equipped with a multiwavelength detector and a flow-through Berthold LB506C1 gamma-detector. Preparative HPLC was done on a Bischof HPLC system (Metrohm AG, Switzerland) with HPLC-pumps 2250 and a Lambda 1010 UV detector (Metrohm AG, Switzerland). CC250/4 Nucleosil 120-3C18 columns from Macherey-Nagel were used for analytical HPLC, and a VP250/21 Nucleosil 200-5C15 column for preparative HPLC. The gradient systems consist-ed of mixtures of water with 0.1% trifluoroacetic acid (TFA) (solvent A) and acetonitrile (solvent B). Quantitative gamma-counting was performed on a COBRA 5003 gamma-system well counter from Packard Instrument Company (Switzerland). Electrospray ionization mass spectrometry (ESI-MS) was carried out with a Finnigan SSQ 7000 spectrometer (Bremen, Germany).
Synthesis. The peptide-chelator conjugates were synthesized by standard Fmoc solid phase synthesis [33] on 2-chlorotritylchloride resin (substitution 0.8 mmol/g) on a Rink peptide-synthesizer Switch 24 (RinkCombichem Technologies, Bubendorf, Switzerland), according to the general procedure described previously [32] . The last step was the coupling of the prochelator DOTA(tBu) 3 to the N-terminus of the peptide. Cleavage of the fully protected conjugates from the resin, oxidative cyclization using iodine, deprotection and HPLC purification led to compounds 1-3 ( Table 1 , Fig. 1 The DOTA-SRIF analogues were complexed with InCl 3 (anhyd.) and Y(NO 3 ) 3 ·5 H 2 O, using the following procedure: ca. 20 µg of the respective DOTA-peptide was heated along with 1.5 eq. of the corresponding metal salt in 150 µl 0.2 M sodium acetate buffer (pH 5) for 25 min. After cooling, 20 µl 0.1 M DTPA (pH 5) was added to complex free metal ions. This mixture was loaded onto a SepPak C 18 cartridge (Millipore, Switzerland), activated using 5 ml MeOH followed by 10 ml H 2 O. [M III (DTPA)] 2− was washed from the cartridge using water. The M III -DOTA-peptide was eluted with methanol and obtained in >97% purity after evaporation of methanol. The radiopeptides were synthesized according to Heppeler et al. [32] and obtained in >99% radiochemical purity at specific activities of >37 GBq/µmol peptide.
For internalization experiments, the DOTA-peptides were labelled to a specific activity of about 37 GBq/µmol peptide; excess InCl 3 was then added and the mixture was purified on a SepPak C 18 cartridge as described above to afford [ 111 In/In III ]DOTA-peptides.
Determination of the somatostatin receptor affinity profiles. Cells stably expressing human sstr1-5 were grown as described previously [24] . All culture reagents were supplied by GIBCO/BRL and Life Technologies (Grand Island, N.Y.). Cell membrane pellets were prepared and receptor autoradiography was performed on pellet sections (mounted on microscope slides) as described in detail previously [24] . For each of the tested compounds, complete displacement experiments were performed with the universal somatostatin radioligand [ 125 I][Leu 8 ,D-Trp 22 ,Tyr 25 ]somatostatin-28 using increasing concentrations of the unlabelled peptide ranging from 0.1 to 1,000 nM. Somatostatin-28 was run in parallel as control using the same increasing concentrations. IC 50 values were calculated after quantification of the data using a computer-assisted image processing system. Tissue standards (autoradiographic [ 125 I]microscales Amersham, UK) containing known amounts of isotopes, cross-calibrated to tissue-equivalent ligand concentrations, were used for quantification [24] . The concentrations of the peptide solutions were measured by UV-spectroscopy (ε NOC,280 mm =9,855).
Cell culture and radioligand internalization studies. Sst 2 receptor expressing AR4-2J cells were obtained from Novartis Pharma (Basel, Switzerland). The AR4-2J cell line was maintained by serial passage in mono-layers in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum, amino acids, vitamins and penicillin-streptomycin, in a humidified 5% CO 2 /air atmosphere at 37°C. Viability of the cells and cell numbers were counted under a microscope with a "Neubauer's counting chamber". For all cell experiments, the cells were seeded at a density of 0.8-1.1 million cells/well in six-well plates and incubated overnight with internalization buffer to obtain a good cell adherence. The loss of cells during the internalization experiments was below 10%. When different radiolabelled peptides were compared in cell experiments, the same cell suspension-containing plates were used. Furthermore, the internalization rate was linearly corrected to 1 million cells/well in all cell experiments.
Medium was removed from the six-well plates and cells were washed once with 2 ml of internalization buffer (DMEM, 1% fetal bovine serum, amino acids and vitamins, pH 7.4). Furthermore, 1.5 ml internalization buffer was added to each well and the plates were incubated at 37°C for about 1 h. Thereafter approximately 500,000 cpm or 0.02 MBq/well 111 In/ 115 In-labelled peptides (2.5 pmol/well) to a final concentration of 1.67 nM were added to the medium and the cells were incubated at 37°C for the indicated time periods in triplicate. Internalization was also studied using three different concentrations of [ 111 In/ 115 In]DOTA-NOC (0.15 pmol/well or 0.1 nM, 2.5 pmol/well or 1.67 nM, and 10 pmol/well or 6.67 nM). To determine non-specific membrane binding and internalization, cells were incubated with radioligand in the presence of 1 µM octreotide. Cellular uptake was stopped by removing medium from the cells and by washing twice with 1 ml of ice-cold phosphate-buffered saline (PBS). Acid wash for 10 min with a 0.1 M glycine buffer pH 2.8 on ice was also performed twice. This was shown previously to be suffi- cient to remove >90% of receptor-bound radioligand. This procedure was performed to distinguish between membrane-bound (acid-releasable) and internalized (acid-resistant) radioligand. Finally, the cells were treated with 1 N NaOH. The culture medium, the receptorbound and the internalized fraction were measured radiometrically in a gamma-counter (Packard, Cobra II).
Radioligand externalization studies. AR4-2J cells (1 million) were incubated with 2.5 pmol/well or 1.67 nM [ 111 In/ 115 In]-labelled DOTA-NOC, DOTA-TOC or DOTA-OC for 120 min, then the medium was removed and the wells were washed twice with 1 ml ice-cold PBS. In each experiment an acid wash for 10 min on ice with a glycine buffer of pH 2.8 was performed to remove the receptor-bound ligand. Cells were then incubated again at 37°C with fresh externalization buffer (DMEM containing 1% fetal bovine serum pH 7.4). After different time points the external medium was removed for quantification of radioactivity in a gamma-counter and replaced with fresh 37°C externalization medium. Internalized ligand was extracted in 1 N NaOH, removed and quantified in a gamma-counter. The recycled fraction was expressed as a percentage of the total internalized amount per 1 million cells, and the stability of the externalized peptides was determined using HPLC after removal of the solvent by a centrifugal evaporator.
Biodistribution. Animal experiments were performed in compliance with the regulations of our institutions and with generally accepted guidelines governing such work. Male Lewis rats (200-250 g) bearing the CA20948 pancreatic tumour (0.4-3.5 g) were used in the experiments. Rats were injected under ether anaesthesia with 2-3 MBq of 0.34 nmol (0.5 µg total peptide mass) [ 111 In]DOTA-NOC in 0.5 ml saline into the dorsal vein of the penis. At several time points, rats were sacrificed under ether anaesthesia. Organs and blood were collected and the radioactivity in these samples was determined using a gamma-counter.
In order to determine the non-specific uptake of the radiopeptides, rats were injected with 0.5 mg octreotide in 0.5 ml saline as a co-injection with the radioligand.
To study the sstr2-, 3-and 5-related specific uptake of [ 111 In]DOTA-NOC in the SRIF receptor-positive tissues, blocking studies were designed with two different somatostatin analogues: DTPA-TATE (sstr2-selective ligand) and In III -DOTA-NOC (sstr2, 3, and 5 affinity). Twenty-five micrograms of these peptides was co-injected with 2-3 MBq [ 111 In]DOTA-NOC (0.34 nmol in 0.5 ml saline) into the dorsal vein of the penis of non-tumour-bearing male Lewis rats. Rats were sacrificed at 24 h and the organs of interest collected and counted for radioactivity.
Statistical methods. Student's t test was used to determine statistical significance. Differences at the 95% confidence level (P<0.05) were considered significant.
Results

Synthesis and radiolabelling
The three DOTA-coupled octapeptides (Fig. 1) were obtained by parallel synthesis on a trityl chloride resin and are part of a small library. The peptides not reported here will be discussed in a more comprehensive chemistry publication. The overall yield of the DOTA peptides was about 30% based on the first Fmoc cleavage. The peptides were prepared and purified to >95% purity by HPLC analysis.
Uncomplexed and metal ion-complexed DOTA peptides were characterized by HPLC, by ESI-MS and by the retained affinity to the somatostatin receptors. Some selected analytical data are given in Table 1 . Labelling cubation period at 37°C. About 85%-95% of totally internalized ligand was specifically internalized. At 30 min and 1.67 nM concentration, [ 111 In]DOTA-NOC showed 7.2%±1.0% specific cell uptake of the total activity administered which increased to 24.8%±1.6% up-take at 4 h. A tendency to reach a plateau was found at 24 h for all three peptides (data not shown). Fig. 4 . The rate of externalization is shown in Fig. 5 . In these experiments, 111 In labelled peptides were allowed to internalize for 120 min; cells were then washed twice with PBS before removing the receptor-bound ligand with the glycine buffer. Medium was then added and removed after 10 min, 30 min, 60 min, 120 min and 240 min and measured for radioactivity. Up to 60 min, the three peptides showed insignificant differences in the externalization rate. To estimate the uptake in sstr-positive organs which may be due to receptor subtype expression other than sstr2, in vivo blocking studies were performed in normal rats using different blocking agents like [DTPA 0 -Tyr 3 -Thr 8 ]-octreotide (DTPA-TATE), an sstr2-specific ligand (IC 50 =3.9±1 nM), and In III -DOTA-NOC (IC 50 : sstr2=2.9±0.1 nM, sstr3= 8±2 nM, sstr5=11.2±3.5 nM). In the adrenals, blocking with only 25 µg of In III -DOTA-NOC showed a very efficient reduction of about 95% whereas 25 µg of the sstr2-selective ligand DTPA-TATE resulted in only about 75% blocking.
Receptor binding and affinity profiles
In vitro internalization studies in AR4-2J cells
A significantly higher blocking effect was also found with In III -DOTA-NOC in the pancreas, pituitary and stomach (data not shown).
Discussion
Receptor scintigraphy with 111 In-DTPA-octreotide has become the "gold standard" for the localization, staging and management of neuroendocrine tumours [34] . The high sensitivity of somatostatin receptor scintigraphy and its ability to change the management of patients with neuroendocrine tumours has been demonstrated in several studies [35, 36, 37, 38, 39] . The same agent has been used for receptor-mediated radionuclide therapy with some success if injected in high doses (6 GBq every 4 weeks) for total doses of up to about 100 GBq [40, 41, 42] . This agent only binds with reasonably high affinity to sstr2 and with low affinity to sstr5 [24] ; in addition, 111 In is not an ideal therapeutic radionuclide. Therefore several groups have developed agents based on somatostatin for improved targeting with positron emitters like 68 [32, 43, 44, 45] . These agents bind with high affinity only to sstr2. Although sstr2 is probably the most abundantly expressed SRIF receptor in human cancer [26] , subtypes sstr1, sstr3, sstr4 and sstr5 may also be of interest. So, our approach is focussed on the identification of analogues with a pan-somatostatin binding profile carrying functional groups for radiolabelling [46] and we have started a programme to use parallel synthesis methods to produce DOTA-coupled octapeptides with the aim of improving the affinity to subtypes other than 2 while maintaining the sstr2 affinity. In a series of compounds we found that [DOTA 0 -1-naphthyl 3 ]-octreotide shows promising properties owing to its high affinity to sstr2, with an IC 50 value of 3.3±0.2 nM if complexed to Y III and 2.9±0.1 nM if complexed to In III , which is three-to fourfold higher than the corresponding value for Y III -DOTA-TOC (IC 50 =11.4±1.7 nM). The new metallopeptides are equipotent to somatostatin-28 on sstr2 and a factor of 7 more potent than Y III -DOTA-LAN. Moreover, they show good affinity to sstr3 and are significantly more potent at sstr5 than Y III -DOTA-LAN. These data do not confirm the pan-somatostatin-like binding affinities of DOTA-LAN published earlier by Smith-Jones et al. [47] . In addition, In III -and Y III -DOTA-NOC show the highest affinities on sstr3. A metal ion dependence is found at sstr3 and sstr4, In III -DOTA-NOC being about three to four times more potent than Y III -DOTA-NOC. A potential explanation for this phenomenon is the difference in the coordination geometry of the two DOTA-metal III complexes, which was documented using 1 H-NMR spectroscopy and X-ray crystallography [48] . Y III -DOTA-OC and Y III -DOTA-NOC are equipotent on sstr3 and about a factor of 6 less potent than the endogenous ligand. There is no metal ion dependence in affinity to sstr5.
Cell uptake and release
In order to obtain a defined and homogeneous metallopeptide, (Fig. 4) . This order follows the receptor affinity of the three radiopeptides, indicating that receptor affinity is the major factor determining the rate of internalization.
As the addition of excess cold octreotide inhibits 90% of the uptake, it can be considered as specific and recep-affinity to sstr2, sstr3 and sstr5. The higher blocking efficiency of In III -DOTA-NOC in the adrenals, pancreas, stomach and pituitary may indicate that part of the radioligand uptake is due to the improved receptor subtype profile. These organs have previously been shown to express different receptor subtypes, at least at the mRNA level: sstr2: adrenals, pituitary and pancreas; sstr3: pituitary, pancreas and stomach; sstr5: adrenals, pituitary, pancreas and stomach [51] .
In conclusion, we have developed a new radiopeptide based on somatostatin which promises to target a broader range of somatostatin receptors and concomitantly a larger spectrum of tumours. These preclinical data indicate that [ 111 In]DOTA-NOC is superior to existing and well-studied radiolabelled somatostatin analogues. Indeed, the predictions from these preclinical studies have been confirmed in initial clinical studies in which excellent images of thyroid cancer patients have been obtained. We assume that [ 90 Y]/[ 177 Lu]DOTA-NOC will have similar favourable properties. tor mediated. In the time interval of the study, no steady state was reached, but the distinct leveling off of [ 111 In/ 115 In]DOTA-NOC uptake indicates that steady state was closely approached; we explain this by the onset of efflux of radiopeptides that were shown to be structurally intact.
If, upon internalization of the radioligand for 2 h, the cells were exposed to the culture medium, a time-dependent efflux of the radiopeptides could again be observed, indicating rapid recycling to the extracellular medium. A steady state was reached already after 2-3 h of release (Fig. 5) . This is in agreement with data that we have published previously on [ 67 Ga]NODAGA-TOC [49] . We interpret this as beginning reactivation of the receptors by the intact externalized peptides and concomitant reendocytosis. The finding that the weakest binder [ 111 In]DOTA-OC apparently shows the most efficient externalization fits with this explanation. The fact that the externalized peptides are still intact upon release is another indication that this is the correct interpretation. It is also in keeping with the conclusion drawn from data obtained by Koenig et al. [50] .
Biodistribution studies
The biodistribution studies in CA20948-bearing tumour rats demonstrated superior uptake of This improvement is likely due to the improved sst2, sst3 and sst5 receptor affinity and the significantly faster rate of internalization, as exemplified in the AR4-2J cell line. The octreotide co-injection experiment demonstrated that the uptake is specific and receptor mediated.
Radiometal labelled radiopeptides show high and persistent kidney uptake, limiting their therapeutic potential. One of the goals in the design of new somatostatin-based radioligands is to reduce their uptake in the kidney. Indeed, the tumour-to-kidney ratio of [ 111 In]DOTA-NOC is improved 2.5-fold compared with [ 111 In]DOTA-TOC.
Despite the distinctly higher lipophilicity of [ 111 In]DOTA-NOC over [ 111 In]DOTA-TOC, the uptake in the liver and the intestines is surprisingly low. In addition, the long residence time of the new radiopeptide in the tumour indicates that it is not only suitable for imaging but also efficacious in targeted radiotherapy when labelled with 90 Y and/or 177 Lu provided that there is no significant difference among these M III radiometals.
To understand the contribution of the high uptake values in SRIF receptor-positive organs due to the different subtype affinities of [ 111 In]DOTA-NOC, the uptake in these tissues was studied using different blocking agents, namely DTPA-TATE, an sstr2-specific ligand with IC 50 =3.9±1 nM, and In III -DOTA-NOC, which has a high
